Psoriasis 1 (PSORS1)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 1

MalaCards integrated aliases for Psoriasis 1:

Name: Psoriasis 1 57 12 72 15
Psoriasis Susceptibility 1 57 29 13 6
Psoriasis Vulgaris 72 17 70 32
Psors1 57 12 72
Psoriasis 72 70
Psoriasis, Susceptibility to, Type 1 39
Psoriasis 1, Susceptibility to 57
Pv 72



57 (Updated 05-Apr-2021)

prevalence 1-2% in northern european populations
onset bimodal, ages 16-22 and ages 57-60
inflammatory arthritis may develop in 30% of patients
types of psoriasis include - plaque, guttate, erythrodermic, pustular
environmental triggers include (koebner's phenomenon), sunburn, hiv infection, beta-hemolytic streptococcal infection, certain medications, stress, and alcohol


psoriasis 1:
Inheritance multifactorial inheritance


External Ids:

Disease Ontology 12 DOID:0111286
OMIM® 57 177900
OMIM Phenotypic Series 57 PS177900
MeSH 44 D011565
ICD10 32 L40.0
MedGen 41 C1867449
SNOMED-CT via HPO 68 3723001 89704006 9014002
UMLS 70 C0033860 C0263361

Summaries for Psoriasis 1

OMIM® : 57 Psoriasis (psoriasis vulgaris; PV) is a chronic inflammatory dermatosis that affects approximately 2% of the population. It is characterized by red, scaly skin patches that are usually found on the scalp, elbows, and knees, and may be associated with severe arthritis. The lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis. The usual age of onset of psoriasis is between 15 and 30 years, although it can present at any age (summary by Matthews et al., 1996). Generalized pustular psoriasis (GPP) is a life-threatening disease characterized by sudden, repeated episodes of high-grade fever, generalized rash, and disseminated pustules, with hyperleukocytosis and elevated serum levels of C-reactive protein (123260) (summary by Marrakchi et al., 2011). GPP often presents in patients with existing or prior psoriasis vulgaris; however, GPP can develop without a history of PV (Sugiura et al., 2013). Palmoplantar pustulosis and acrodermatitis continua of Hallopeau represent acral forms of pustular psoriasis that have historically been grouped with GPP (summary by Setta-Kaffetzi et al., 2013). Nestle et al. (2009) provided a detailed review of the pathogenesis and genetics of psoriasis. (177900) (Updated 05-Apr-2021)

MalaCards based summary : Psoriasis 1, also known as psoriasis susceptibility 1, is related to psoriasis 2 and psoriasis 8, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 1 is HLA-C (Major Histocompatibility Complex, Class I, C), and among its related pathways/superpathways are Cellular senescence (KEGG) and Keratinization. The drugs Metformin and Esomeprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and endothelial, and related phenotypes are arthritis and nail pits

Disease Ontology : 12 A psoriasis that has material basis in variation in HLA-C on chromosome 6p21.33.

UniProtKB/Swiss-Prot : 72 Psoriasis 1: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

Related Diseases for Psoriasis 1

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1257)
# Related Disease Score Top Affiliating Genes
1 psoriasis 2 32.6 LCE3C LCE3B CARD14
2 psoriasis 8 31.7 PSORS1C3 NAT9 CDSN CCHCR1 CARD14
3 spondyloarthropathy 1 31.4 IL23R HLA-B CCR6
4 psoriasis 14, pustular 31.4 TNIP1 LCE3C LCE3B CARD14
5 allergic contact dermatitis 30.7 LCE3C LCE3B CCR6
6 spondylitis 30.6 MICA IL23R HLA-C HLA-B CCR6
7 pustulosis of palm and sole 30.4 CCR6 CARD14
8 nail disease 30.4 TRAF3IP2 IL23R CCR6
9 pityriasis rosea 30.4 HLA-C HLA-B
10 leprosy 3 30.3 IL23R HLA-B CCR6
11 stevens-johnson syndrome/toxic epidermal necrolysis 30.3 HLA-C HLA-B
12 guttate psoriasis 30.3 HLA-C CDSN
13 celiac disease 1 30.2 IL23R HLA-C HLA-B CCR6
14 histoplasmosis 30.0 MICA HLA-B CCR6
15 iritis 29.9 HLA-B CCR6
16 peeling skin syndrome 29.8 PSORS1C2 PSORS1C1 CDSN
17 severe cutaneous adverse reaction 29.8 PSORS1C1 HLA-C HLA-B
18 panuveitis 29.7 IL23R HLA-B CCR6
19 epstein-barr virus hepatitis 29.5 HLA-C HLA-B
20 skin disease 29.5 PSORS1C1 HLA-C HLA-B CDSN CCR6 CARD14
21 birdshot chorioretinopathy 29.5 HLA-C CCR6
22 vogt-koyanagi-harada disease 29.5 IL23R HLA-C HLA-B
23 psoriasis 5 29.4 PSORS1C3 NAT9 HLA-C CDSN CARD14
24 psoriasis 3 29.4 PSORS1C3 NAT9 CDSN CCHCR1 CARD14
25 psoriasis 6 29.4 PSORS1C3 NAT9 CDSN CCHCR1 CARD14
26 chronic mucocutaneous candidiasis 29.2 TRAF3IP2 IL23R CCR6
27 psoriasis 9 29.2 PSORS1C3 NAT9 LCE3C LCE3B CDSN CARD14
28 psoriasis 7 28.9 PSORS1C3 PSORS1C1 NAT9 IL23R CDSN CCHCR1
29 psoriasis 10 28.8 PSORS1C3 NAT9 LCE3D LCE3C LCE3A CCHCR1
30 behcet syndrome 28.7 PSORS1C1 MICA IL23R HLA-C HLA-B CCR6
31 psoriasis 4 28.7 NAT9 LCE3C LCE3B LCE3A HLA-C CDSN
32 psoriatic arthritis 28.4 TRAF3IP2 TNIP1 MICA LCE3C LCE3B IL23R
33 psoriasis 27.4 TRAF3IP2 PSORS1C3 PSORS1C2 PSORS1C1 MICA LCE3B
34 pustular psoriasis 11.7
35 psoriasis 13 11.6
36 psoriasis 11 11.5
37 psoriasis 15, pustular 11.4
38 pustulosis palmaris et plantaris 11.4
39 psoriasis 12 11.4
40 psoriatic juvenile idiopathic arthritis 11.4
41 psoriasis 15 11.3
42 tranebjaerg svejgaard syndrome 11.2
43 arthritis 11.2
44 juvenile rheumatoid arthritis 11.1
45 mental retardation and psoriasis 11.1
46 impetigo herpetiformis 11.1
47 geographic tongue 11.0
48 vitiligo-associated multiple autoimmune disease susceptibility 1 11.0
49 parapsoriasis 11.0
50 singleton-merten syndrome 1 11.0

Graphical network of the top 20 diseases related to Psoriasis 1:

Diseases related to Psoriasis 1

Symptoms & Phenotypes for Psoriasis 1

Human phenotypes related to Psoriasis 1:

# Description HPO Frequency HPO Source Accession
1 arthritis 31 HP:0001369
2 nail pits 31 HP:0001803
3 psoriasiform dermatitis 31 HP:0003765
4 onychomadesis 31 HP:0025088

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Skin Nails Hair Nails:
nail pitting
dystrophic nail changes

Skin Nails Hair Skin:
red, raised, scaly skin patches (elbows, knees, scalp)

hla antigens cw6, b13, b17 associated with psoriasis

arthritis (large joints, small joint, or central axial skeleton)

Skin Nails Hair Skin Histology:
lymphocytic inflammatory infiltrate
epidermal hyperproliferation
abnormal keratinocyte differentiation
koebner phenomenon

Clinical features from OMIM®:

177900 (Updated 05-Apr-2021)

UMLS symptoms related to Psoriasis 1:

pruritus; exanthema; psoriasiform rash

Drugs & Therapeutics for Psoriasis 1

Drugs for Psoriasis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 374)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Metformin Approved Phase 4 657-24-9 4091 14219
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
Desonide Approved, Investigational Phase 4 638-94-8 5311066
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
Sodium citrate Approved, Investigational Phase 4 68-04-2
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
Desoximetasone Approved Phase 4 382-67-2 5311067
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5311052 5282493
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
Ustekinumab Approved, Investigational Phase 4 815610-63-0
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Vedolizumab Approved Phase 4 943609-66-3
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
Adalimumab Approved, Experimental Phase 4 331731-18-1 16219006
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
Capsaicin Approved Phase 4 404-86-4 1548943
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
Trichostatin A Experimental Phase 4 58880-19-6
32 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
33 Citrate Phase 4
34 Anticoagulants Phase 4
35 diuretics Phase 4
36 Chelating Agents Phase 4
37 Hydrocortisone hemisuccinate Phase 4
38 Hydrocortisone 17-butyrate 21-propionate Phase 4
39 Vitamin B9 Phase 4
40 Folic Acid Antagonists Phase 4
41 Vitamin B Complex Phase 4
42 Folate Phase 4
43 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
44 Myeloma Proteins Phase 4
45 Paraproteins Phase 4
46 Hydrocortisone-17-butyrate Phase 4
47 Bronchodilator Agents Phase 4
48 Anti-Allergic Agents Phase 4
49 Tin Fluorides Phase 4
50 Clocortolone pivalate Phase 4

Interventional clinical trials:

(show top 50) (show all 1488)
# Name Status NCT ID Phase Drugs
1 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
2 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
3 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
4 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
5 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
6 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
7 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
8 Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study Unknown status NCT03629639 Phase 4 Metformin
9 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
10 Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis Unknown status NCT02829424 Phase 4 Methotrexate;Methotrexate Placebo
11 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
12 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
13 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
14 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
15 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
16 An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab Unknown status NCT03827876 Phase 4 Enstilar 0.005%-0.064% Topical Foam
17 A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis Unknown status NCT03587194 Phase 4 Otezla
18 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
19 Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis Unknown status NCT03453190 Phase 4
20 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
21 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
22 Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients Unknown status NCT03904680 Phase 4 Methotrexate;Vitamin D
23 Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis Completed NCT03348462 Phase 4 ethosomal preparation of anthralin;liposomal preparation of anthralin
24 Can an App Supporting Psoriasis Patients Improve Adherence to Topical Treatment? A Single-blind Randomized Controlled Trial Completed NCT02858713 Phase 4 Calcipotriene + Betamethasone Dipropionate
25 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
26 Energy-restricted, n-3 Polysaturated Fatty Acids-rich Diet Improves the Clinical Response to Immuno-modulating Drugs in Obese Patients With Plaque-type Psoriasis: a Randomized Control Clinical Trial. Completed NCT01876875 Phase 4
27 A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy Completed NCT01761019 Phase 4 Taclonex Topical Suspension
28 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo
29 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
30 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
31 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis Completed NCT03055494 Phase 4
32 Enbrel® in Psoriatic Arthritis Completed NCT00111124 Phase 4 Enbrel®
33 A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
34 An Investigator-Initiated, Assessor Blinded, Randomized Study Comparing the Mechanism of Action of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis. Completed NCT00932113 Phase 4 Methotrexate;Adalimumab (Humira)
35 An Open Label, Prospective Cohort Pilot Study to Evaluate the Efficacy and Safety of Etanercept in the Treatment of Moderate to Severe Plaque Psoriasis in Patients Who Have Not Had an Adequate Response to Adalimumab Completed NCT00833729 Phase 4 etanercept
36 Pilot Study on the Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis Completed NCT00940862 Phase 4
37 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT02690701 Phase 4 Secukinumab 300 mg
38 A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color Completed NCT03506477 Phase 4 Enstilar® foam;Vehicle foam
39 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
40 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
41 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
42 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
43 Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed NCT00216892 Phase 4 Calcipotriol, (calcipotriol + betamethasone)
44 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris Completed NCT00640393 Phase 4 Etanercept
45 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex
46 Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris Completed NCT02004574 Phase 4 Calcipotriol/betamethasone dipropionate gel
47 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
48 A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis Completed NCT02125279 Phase 4 Calcitriol
49 A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed NCT03942042 Phase 4 Ixekizumab
50 Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept

Search NIH Clinical Center for Psoriasis 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Aloe vera preparation
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
Coal Tar
Coal tar extract
Coal tar pitch volatiles
Cod Liver Oil
Colloid sulfur
Fish Liver Oils
Fluocinolone Acetonide
Methotrexate Sodium
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid

Genetic Tests for Psoriasis 1

Genetic tests related to Psoriasis 1:

# Genetic test Affiliating Genes
1 Psoriasis Susceptibility 1 29 HLA-C

Anatomical Context for Psoriasis 1

MalaCards organs/tissues related to Psoriasis 1:

Skin, Liver, Endothelial, T Cells, Bone, Pituitary, Neutrophil

Publications for Psoriasis 1

Articles related to Psoriasis 1:

(show top 50) (show all 210)
# Title Authors PMID Year
Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. 61 6 57
16642438 2006
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. 57 61
22521419 2012
Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. 57 61
19525279 2009
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. 57 61
16235096 2005
Mapping of the major psoriasis-susceptibility locus (PSORS1) in a 70-Kb interval around the corneodesmosin gene (CDSN). 57 61
15529278 2005
Transgenic mouse models support HCR as an effector gene in the PSORS1 locus. 57 61
15190014 2004
Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. 57 61
12648227 2003
Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. 61 57
12485440 2002
Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. 61 57
12148091 2002
Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. 57 61
11875053 2002
The HCR gene on 6p21 is unlikely to be a psoriasis susceptibility gene. 57 61
11348465 2001
Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. 61 57
11134234 2001
Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. 57 61
10801386 2000
Familial psoriasis and HLA-B: unambiguous support for linkage in 97 published families. 61 57
9694251 1998
Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. 57
32758448 2020
Myeloperoxidase Modulates Inflammation in Generalized Pustular Psoriasis and Additional Rare Pustular Skin Diseases. 57
32758447 2020
Clinical improvement in psoriasis with specific targeting of interleukin-23. 57
25754330 2015
The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. 57
23698098 2013
Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. 57
23303454 2013
Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. 57
21848462 2011
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. 57
20953190 2010
Cutting edge: A critical functional role for IL-23 in psoriasis. 57
20956338 2010
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. 57
19684581 2009
Psoriasis. 57
19641206 2009
Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. 57
18923449 2009
Psoriasis is associated with increased beta-defensin genomic copy number. 57
18059266 2008
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. 57
17873860 2007
Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. 57
17603494 2007
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. 57
17287478 2007
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). 57
16380428 2005
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. 57
16163348 2005
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. 57
14981113 2004
The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. 57
12851855 2003
Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. 57
12588373 2003
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. 57
12461524 2003
HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. 57
11841557 2002
Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. 57
11851889 2002
Interleukin-10 promoter polymorphism in psoriasis. 57
11407990 2001
Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families. 57
11556968 2001
HLA-C and guttate psoriasis. 57
11122018 2000
The OTF3 gene polymorphism confers susceptibility to psoriasis independent of the association of HLA-Cw*0602. 57
11069619 2000
A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. 57
10888604 2000
Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. 57
10577939 1999
Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. 57
10545595 1999
Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. 57
10469328 1999
Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. 57
10332047 1999
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. 57
10225967 1999
Psoriasis linkage in the HLA region. 57
10053024 1999
Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. 57
9858851 1999
Vitamin D receptor polymorphism is associated with psoriasis. 57
9886274 1999

Variations for Psoriasis 1

ClinVar genetic disease variations for Psoriasis 1:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HLA-C HLA-C, HLA-Cw6 Variation risk factor 14906 GRCh37:

Expression for Psoriasis 1

Search GEO for disease gene expression data for Psoriasis 1.

Pathways for Psoriasis 1

Pathways related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.63 TRAF3IP2 HLA-C HLA-B
Show member pathways
3 11.26 MICA HLA-C HLA-B
4 10.55 HLA-C HLA-B

GO Terms for Psoriasis 1

Cellular components related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-C HLA-B
2 MHC class I protein complex GO:0042612 8.62 HLA-C HLA-B

Biological processes related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-positive bacterium GO:0050830 9.58 LCE3C LCE3B LCE3A
2 keratinization GO:0031424 9.56 LCE3D LCE3C LCE3B LCE3A
3 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.46 HLA-C HLA-B
4 positive regulation of T cell mediated cytotoxicity GO:0001916 9.43 IL23R HLA-B
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.37 HLA-C HLA-B
6 killing of cells of other organism GO:0031640 9.33 LCE3C LCE3B LCE3A
7 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.32 HLA-C HLA-B
8 defense response to Gram-negative bacterium GO:0050829 9.26 LCE3C LCE3B LCE3A IL23R
9 epidermis development GO:0008544 9.02 LCE3D LCE3C LCE3B LCE3A CDSN

Molecular functions related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 TAP binding GO:0046977 8.62 HLA-C HLA-B

Sources for Psoriasis 1

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....